Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
The global cancer treatment market is experiencing rapid growth, driven by rising cancer incidence, aging population and increasing demand for safer, more effective therapies. Per the American Cancer Society, in the United States alone, over 2 million new cancer cases and 618,000 related deaths are projected for 2025.
Breakthroughs in immunotherapy, targeted treatments, and personalized cancer vaccines are reshaping the oncology landscape. These next-generation therapies offer greater precision and improved outcomes, supporting strong market expansion.
Major pharma companies — including Novartis NVS, AstraZeneca AZN, Johnson & Johnson JNJ, Pfizer PFE, AbbVie ABBV, Bristol Myers Squibb and Eli Lilly LLY — are investing heavily in cutting-edge approaches like antibody-drug conjugates (ADCs) and immuno-oncology agents. Meanwhile, smaller biotechs are driving innovation, making them attractive acquisition targets for larger players seeking to enhance their oncology pipelines.
As scientific progress accelerates, the oncology market is poised for robust, long-term growth — offering compelling opportunities for investors.
These factors highlight the huge potential of cancer-focused companies. With our thematic screens, you can easily spot stocks tied to trends shaping the future of investing. If the cancer space appeals to you and you're looking to align your portfolio with this rising trend, now might be the time to consider stocks like J&J, Novartis and Allogene Therapeutics ALLO
3 Cancer Stocks in Focus
J&J's Oncology segment comprises around 27% of its total revenues. Its oncology sales rose 22.3% on an operational basis in the second quarter of 2025 to $6.3 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant plus Lazcluze, contributed significantly to growth as they witnessed strong launches.
On its second-quarter conference call, J&J stated that it expects its oncology sales to reach $50 billion by the end of the decade. J&J seems quite confident in the target, citing strong growth in its marketed cancer drugs and the potential of upcoming launches like TAR-200 in bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer (NSCLC). TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. The subcutaneous formulation of Rybrevant plus Lazcluze has been recommended for approval in the EU while it is under review in the United States.
J&J's oncology pipeline has gained strong momentum in the last year and a half, with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio.
J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Novartis has a diverse oncology portfolio, including targeted therapies and immunotherapies.
The FDA's approval of Kisqali, its CDK4/6 inhibitor for the first-line treatment of postmenopausal women with HR+/HER2 advanced or metastatic breast cancer, significantly boosted the company's oncology portfolio, with the drug now being one of the top growth drivers for the company. In particular, Kisqali has shown robust uptake in the metastatic breast cancer setting. The recent approval of a broader label for Kisqali in the United States and the EU should further fuel its sales. Kisqali recorded sales of $1.1 billion in the second quarter of 2025, up 64% year over year.
Other new oncology drugs like Pluvicto (PSMA-positive metastatic castration-resistant prostate cancer) and Scemblix (chronic myeloid leukemia) also put up a stellar performance, setting the momentum for the coming years as well. Novartis' oncology sales rose 20% in constant currency terms to $4.3 billion in the second quarter of 2025.
In 2024, Novartis acquired Mariana Oncology and Germany-based MorphoSys AG, which strengthened its oncology pipeline.
This Zacks Rank #2 company is also investing in research to develop treatments for both common and rare cancers, focusing on precision medicine strategies.
Allogene Therapeutics is focused on developing allogeneic CAR T therapies for treating cancer, especially hematologic indications with high unmet needs.
This Zacks Rank #2 company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — cemacabtagene ansegedleucel (cema-cel or formerly ALLO-501A) and ALLO-316 for cancer indications.
Lead candidate, cema-cel, is being developed as a frontline treatment for patients with large B-cell lymphoma (LBCL). In this regard, the company has initiated the pivotal phase II ALPHA3 study to evaluate cema-cel in patients with first-line LBCL.
ALLO-316, the company's first CAR T candidate for solid tumors, is being evaluated in the TRAVERSE study in adults with advanced or metastatic renal cell carcinoma. Data from the study has shown that the therapy-induced early anti-tumor activity with deepening responses over time, especially in heavily pre-treated patients with high CD70 expression.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
Novartis AG (NVS) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
3 days ago
- UPI
Firefighters at higher risk for many cancers, new study finds
A newly published study "supports the growing body of research linking occupation as a firefighter to cancer risk," health researchers say. File Photo (2023) by Bill Greenblatt/UPI | License Photo Firefighters work hard saving lives, and in process put their own lives at heightened risk from skin, kidney and other types of cancers, a new American Cancer Society (ACS) study finds. "Although this isn't favorable news, this study shines a spotlight on the long-term risks firefighters face beyond the immediate dangers of fighting a fire," said lead author Lauren Teras, the ACS' senior scientific director of epidemiology research. "Continued efforts to safeguard the health of firefighters by increasing access to cancer screening, early detection, and prevention are paramount," she added in a news release. The findings were published July 29 in the International Journal of Epidemiology. The study drew on data from the ACS Cancer Prevention Study-II, which tracked rates of cancer deaths over 36 years for people who were cancer-free when the study began in 1982. More than 470,000 people enrolled in the study were firefighters, and their rates of cancer death were compared to male participants working in other fields. Overall, the study "supports the growing body of research linking occupation as a firefighter to cancer risk," conclude Teras and her colleagues. Risks were highest for skin cancers (a 72% rise in risk among firefighters) and kidney cancer (a 39% higher risk). Smaller increases in risk were observed for cancers of the lung (8% higher odds), prostate (14%) and colon (15%), the team reported. According to the researchers, the higher risk for fatal skin cancers might stem from the fact that firefighters are often outside without proper skin protection. Taking better precautions from sun exposure might help protect them, Teras said. The slightly higher risk for lung cancer only arose among firefighters who'd been on the the job for 30 or more years, the researchers pointed out. Teras noted that a prior study from the International Agency for Research on Cancer (IARC) found evidence that firefighting raises the odds for mesothelioma and bladder cancer, but was inconclusive as to other tumor types. "Our findings support the growing body of research linking firefighter exposures to cancer risk," Teras said in an ACS news release. "The associations with skin, kidney, prostate and colorectal cancer notably help to fill gaps for cancers that were considered to have limited or inadequate evidence in the previous IARC review." More information There's more on preventing skin cancer at the Skin Cancer Foundation. SOURCES: American Cancer Society, news release, July 28, 2025; International Journal of Epidemiology, July 29, 2025 Copyright © 2025 HealthDay. All rights reserved.
Yahoo
3 days ago
- Yahoo
Apyx Medical Corporation to Participate in the Canaccord Genuity 45th Annual Growth Conference
CLEARWATER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ('Apyx Medical;' the 'Company'), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that management will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, in Boston, MA. Charlie Goodwin, the Company's President and Chief Executive Officer, and Matt Hill, the Company's Chief Financial Officer, will participate in a fireside chat on Tuesday, August 12, 2025, at 4:00pm ET and will hold one-on-one meetings with investors throughout the day. The fireside chat will be accessible via live webcast here, and a replay will be available on the Events section of Apyx Medical's Investor Relations website at About Apyx Medical Corporation: Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people's lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and now the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at Investor Relations Contact:Jeremy Feffer Managing Director LifeSci Advisors OP: 212-915-2568 jfeffer@
Yahoo
3 days ago
- Yahoo
J&J tests direct CAR-T marketing with first Carvykti ad
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Available cell therapies for cancer aren't easy treatments to receive. Personalized to each patient, the drugs are complicated and time-consuming to manufacture, and must be delivered and administered on an exacting schedule. And because they come with serious risks, patients need to remain close to the hospital where they were treated for weeks of monitoring. All of these characteristics make Johnson & Johnson's choice to roll out direct-to-consumer advertising for Carvykti, a cell therapy it sells for the blood cancer multiple myeloma, somewhat unexpected. The ad, which will air on streaming services like YouTube, Paramount and Roku, is J&J's first for the drug and a rare instance of DTC marketing for this kind of cell therapy, known as CAR-T. According to June Lanoue, J&J's head of U.S. hematology, the company aims to raise awareness about cell therapy, particularly among patients who may not be receiving care from the kind of specialized academic centers where CAR-T is often given. Carvykti is currently approved in the U.S. to treat multiple myeloma in patients whose disease either relapsed or becomes resistant to treatment after an initial round of therapy. Another CAR-T therapy, called Abecma and sold by Bristol Myers Squibb, is also cleared for this use, but only after two or more prior lines of treatment. Among these 'relapsed, refractory' patients, about half are treated at community oncology centers, Lanoue said. 'The actual awareness level of these options is very low,' she added. 'In the community, if they're not able to get it, doctors are not talking about and therefore they don't have visibility to having a new option.' J&J's choice to advertise is a signal of confidence in its ability to manufacture enough Carvykti to meet any rise in demand. Early on in the drug's launch, production challenges forced the company to limit orders from treating centers. (Bristol Myers ran into similar issues.) 'We feel very confident around production,' said Lanoue. Treatment sites can 'order Carvykti without any constraint.' The launch of the ad is also well-timed, as it comes several weeks after the Food and Drug Administration took steps to improve access to CAR-T treatment broadly. The agency eased some side effect reporting requirements and lessened the time it mandates patients stay near their treating facility for monitoring. It also said patients could resume driving or operating machinery sooner after treatment than previously prescribed. 'We think it will give more opportunity to more patients who [live at] a little bit further distance to be able to receive Carvykti,' Lanoue said. J&J's 120-second ad introduces a composite patient, 'Marvin,' and describes the heavy burden of injections and pills typically used to control multiple myeloma. Carvykti, by contrast, is a one-time infusion that can deliver lasting benefits in some. Recent follow-up data from an early study of around 100 patients treated with Carvykti showed that, at five years, one-third had not yet experienced disease progression. A story published in June by The New York Times that highlighted these findings led to more patients requesting information about Carvykti, according to Lanoue. J&J did not share how much it's spending on this marketing campaign, but Lanoue said it is 'significantly less' than what a pharmaceutical company would typically spend on a regular TV advertisement. 'This is not a share of voice play; this is ultra targeted,' she added. Sales of Carvykti reached $439 million in the three months between April and June. The company expects peak annual sales to eventually eclipse $5 billion. Editor's note: After this story was published, J&J updated the list of streaming services where its ad will appear and removed Hulu for the time being. Recommended Reading FDA takes major step to ease access to CAR-T therapy Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
